Legal & General Group Plc Buys 8,614 Shares of Rapport Therapeutics (NASDAQ:RAPP)

Legal & General Group Plc grew its stake in shares of Rapport Therapeutics (NASDAQ:RAPP) by 947.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 9,523 shares of the company’s stock after acquiring an additional 8,614 shares during the quarter. Legal & General Group Plc’s holdings in Rapport Therapeutics were worth $169,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Alliancebernstein L.P. boosted its holdings in shares of Rapport Therapeutics by 0.9% in the 4th quarter. Alliancebernstein L.P. now owns 1,098,415 shares of the company’s stock valued at $19,486,000 after purchasing an additional 9,494 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Rapport Therapeutics by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 210,676 shares of the company’s stock worth $3,738,000 after buying an additional 8,928 shares in the last quarter. Jennison Associates LLC bought a new stake in Rapport Therapeutics during the 4th quarter worth $1,105,000. State Street Corp bought a new position in Rapport Therapeutics in the third quarter valued at about $1,189,000. Finally, Norges Bank bought a new position in Rapport Therapeutics in the 4th quarter valued at approximately $860,000.

Insiders Place Their Bets

In other Rapport Therapeutics news, Director Wendy B. Young bought 6,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were acquired at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the purchase, the director now owns 6,000 shares in the company, valued at approximately $61,260. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Troy A. Ignelzi bought 9,900 shares of the stock in a transaction on Wednesday, March 12th. The shares were bought at an average price of $10.10 per share, for a total transaction of $99,990.00. Following the purchase, the chief financial officer now directly owns 9,900 shares in the company, valued at approximately $99,990. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here.

Analysts Set New Price Targets

A number of equities research analysts have commented on RAPP shares. JMP Securities began coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They issued a “market outperform” rating and a $28.00 price target on the stock. Citizens Jmp initiated coverage on shares of Rapport Therapeutics in a research report on Tuesday, April 8th. They set a “mkt outperform” rating for the company. Four analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $32.67.

Rapport Therapeutics Stock Up 0.2 %

Shares of NASDAQ:RAPP opened at $11.47 on Friday. The company’s fifty day moving average is $9.90 and its 200 day moving average is $16.18. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $29.74. The stock has a market cap of $418.63 million and a PE ratio of -0.83.

Rapport Therapeutics Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.